Opendata, web and dolomites

EpiPredict SIGNED

Epigenetic regulation of endocrine therapy resistance in breast cancer: A systems medicine approach to predict treatment outcome

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EpiPredict project word cloud

Explore the words cloud of the EpiPredict project. It provides you a very rough idea of what is the project "EpiPredict" about.

outcome    interference    private    industry    fellows    multidisciplinary    considering    employs    technologies    scientists    positive    frequent    science    underlying    epipredict    tamoxifen    er    personal    ample    ranging    generation    whilst    succeed    monitoring    successfully    predict    extra    clinical    computational    medical    intersectorial    treatment    mindset    central    innovative    interacting    parties    environments    estrogen    protein    narrowly    public    ict    supradisciplinary    reversal    socio    trained    diseases    computation    esrs    involvement    careers    beneficiaries    setting    epigenetic    entrepreneurial    boost    epigenetics    drive    markers    training    visiting    stage    compete    medicine    train    prevention    receptor    consideration    young    exposure    cancer    iterative    industrial    breast    achievements    experts    academia    biotech    cohort    translational    scene    diagnostic    pharma    impulses    resistance    12    pharmaceutical    gene    academic    combining    equipped    patient    personalized    job    ensures    profiling    systematic    mission    leaders    tools    urgent   

Project "EpiPredict" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT VAN AMSTERDAM 

Organization address
address: SPUI 21
city: AMSTERDAM
postcode: 1012WX
website: www.uva.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://redict.eu
 Total cost 2˙797˙697 €
 EC max contribution 2˙797˙697 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2014
 Funding Scheme MSCA-ITN-ETN
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) coordinator 766˙122.00
2    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 546˙575.00
3    DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG DE (HEIDELBERG) participant 498˙432.00
4    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA IT (MILANO) participant 258˙061.00
5    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 255˙374.00
6    Epiontis GmbH DE (Berlin) participant 249˙216.00
7    SZEGEDI BIOLOGIAI KUTATOKOZPONT HU (SZEGED) participant 223˙913.00
8    CLINICAGENO LIMITED UK (COULSDON SURREY) participant 0.00
9    AHT Management Kft HU (Budapest) partner 0.00
10    Biotecture Ltd NL (Amsterdam) partner 0.00
11    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) partner 0.00
12    FH JOANNEUM GESELLSCHAFT MBH AT (GRAZ) partner 0.00
13    Rathenau Instituut NL (Amsterdam) partner 0.00
14    STIFTELSEN FRAUNHOFER-CHALMERS CENTRUM FOR INDUSTRIMATEMATIK SE (GOETEBORG) partner 0.00
15    Synvolux Therapeutics BV NL (Leiden) partner 0.00

Map

 Project objective

The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER) breast cancer, considering five resistance interacting pathways. Given the frequent Tamoxifen treatment failure, resistance prevention and reversal is an urgent clinical problem that is central in EpiPredict. The EpiPredict intersectorial training programme employs a timely systems medicine approach combining next-generation systematic epigenetic, gene/protein profiling with innovative gene-specific epigenetic interference technologies for iterative computational modelling. Together the ESRs will identify key epigenetic changes underlying Tamoxifen induced resistance. This will provide an important step towards diagnostic markers/tools to predict treatment outcome and response monitoring setting the scene for breast cancer personalized medicine. The fellows will be trained by experts from 6 academic and 2 non-academic beneficiaries and 7 partner organizations (1 academic, 6 non-academic including industrial/socio-public parties) and 5 visiting scientists, from fields ranging from epigenetics to both computation and medicine. Strong involvement of the private sector ensures exploitation of EpiPredict achievements and exposure of the ESRs to an entrepreneurial mindset. The cohort of supradisciplinary researchers represents a new generation of research leaders equipped to address complex diseases whilst taking personalized patient aspects into consideration. They will be equipped to compete successfully and succeed in their personal careers. EpiPredict will boost academia and pharma/biotech environments, providing extra impulses to drive European translational science, systems medicine, pharmaceutical industry, and Medical ICT offering ample job opportunities.

 Deliverables

List of deliverables.
Prizes second annual meeting Other 2019-07-10 14:48:58
PhD degrees Other 2019-07-10 14:48:58
Prizes fourth annual meeting Other 2019-07-10 14:48:58
Prizes third annual meeting Other 2019-07-10 14:48:58
Prize first annual meeting Other 2019-07-10 14:48:57

Take a look to the deliverables list in detail:  detailed list of EpiPredict deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Özge Saatci, Simone Borgoni, Özge Akbulut, Selvi Durmuş, Umar Raza, Erol Eyüpoğlu, Can Alkan, Aytekin Akyol, Özgür Kütük, Stefan Wiemann, Özgür Şahin
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer
published pages: 2251-2269, ISSN: 0950-9232, DOI: 10.1038/s41388-017-0108-9
Oncogene 37/17 2019-07-10
2017 D Goubert, W F Beckman, P J Verschure, M G Rots
Epigenetic editing: towards realization of the curable genome concept
published pages: 13006, ISSN: 2057-1739, DOI: 10.1088/2057-1739/aa5cc0
Convergent Science Physical Oncology 3/1 2019-07-10
2018 Thierry D.G.A. Mondeel, Stefania Astrologo, Yanfei Zhang, Hans V. Westerhoff
NET works after all? Engineering robustness through diversity
published pages: 128-137, ISSN: 2405-8963, DOI: 10.1016/j.ifacol.2018.09.007
IFAC-PapersOnLine 51/19 2019-07-10
2016 Juan Song, David Cano Rodriguez, Melanie Winkle, Rutger A.F. Gjaltema, Désirée Goubert, Tomasz P. Jurkowski, Irene H Heijink, Marianne G. Rots, Machteld N Hylkema
Targeted epigenetic editing of SPDEF reduces mucus production in lung epithelial cells
published pages: ajplung.00059.20, ISSN: 1040-0605, DOI: 10.1152/ajplung.00059.2016
American Journal of Physiology - Lung Cellular and Molecular Physiology 2019-07-10
2017 Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Giacomo Corleone, Sonia Fabris, Hermannus Kempe, Pernette J Verschure, Iros Barozzi, Valentina Vircillo, Sung-Pil Hong, Ylenia Perone, Massimo Saini, Andreas Trumpp, Giuseppe Viale, Antonino Neri, Simak Ali, Marco Angelo Colleoni, Giancarlo Pruneri, Saverio Minucci
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
published pages: 444-450, ISSN: 1061-4036, DOI: 10.1038/ng.3773
Nature Genetics 49/3 2019-07-10

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

NEWAVE (2019)

Next Water Governance

Read More  

TACT (2020)

Targeted Anti-Cancer Therapies

Read More  

INSPIRE (2019)

INNOVATIVE GROUND INTERFACE CONCEPTS FOR STRUCTURE PROTECTION

Read More